Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.48 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.48 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32667347 | 0.95 | SCN5A (0.45) | SCN5ASCN2ASCN10ATP53MDM2 | |
| SCHEMBL32667638 | 0.89 | BCL2L1 (0.40) | SCN5ASCN2ASCN10ABCL2L1PTGS2 | |
| SCHEMBL32667349 | 0.88 | MAPK14 (0.43) | SCN5ASCN2ASCN10APTGS2PTGS1 | |
| SCHEMBL32667337 | 0.85 | BCL2L1 (0.38) | SCN5ASCN2ASCN10ABCL2L1PTGS2 | |
| SCHEMBL32667388 | 0.84 | CHRNA4 (0.42) | BCL2L1HRH4 | |
| SCHEMBL32667589 | 0.82 | BCL2L1 (0.38) | TP53MDM2BCL2L1PTGS2PTGS1 | |
| SCHEMBL32667649 | 0.82 | IDH1 (0.40) | SCN5ASCN2ASCN10ATP53MDM2 | |
| SCHEMBL30790591 | 0.82 | MEN1 (0.54) | BCL2L1POLB | |
| SCHEMBL32667718 | 0.81 | BCL2L1 (0.38) | TP53MDM2BCL2L1PTGS2PTGS1 | |
| SCHEMBL32667526 | 0.79 | BCL2L1 (0.38) | SCN5ASCN2ASCN10ABCL2L1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028326-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | GLUETACS THERAPEUTICS SHANGHAI CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
| CN-117881668-A | Compound based on isoindoline substituted glutarimide skeleton and application thereof | 标新生物医药科技(上海)有限公司 | 2024-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028326-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | CDR2, CYC1, CLN6 | SCN5A 304/4885SCN2A 165/4885SCN10A 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.